SCHEMBL4549036

SCHEMBL4549036

CNC(=O)c1cccc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 19/20 0.78
AURKA O14965 10/20 0.78
TEK Q02763 10/20 0.78
AURKB Q96GD4 9/20 0.78
MET P08581 9/20 0.78
LCK P06239 7/20 0.74
FLT1 P17948 4/20 0.65
FLT4 P35916 3/20 0.65
LYN P07948 3/20 0.60
FGFR1 P11362 2/20 0.60
FGFR2 P21802 2/20 0.60
RET P07949 2/20 0.60
PDXK O00764 1/20 0.60
RIPK2 O43353 1/20 0.60
PDGFRB P09619 1/20 0.60
FGFR3 P22607 1/20 0.60
DDR1 Q08345 1/20 0.60
DDR2 Q16832 1/20 0.60
ABL1 P00519 1/20 0.58
FGR P09769 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2748231 0.89 KDR (0.83) KDRAURKATEKAURKBMET
SCHEMBL2746953 0.89 KDR (0.85) KDRAURKATEKAURKBMET
SCHEMBL4548969 0.88 KDR (1.00) KDRAURKATEKAURKBMET
SCHEMBL4549035 0.88 KDR (1.00) KDRAURKATEKAURKBMET
SCHEMBL2748090 0.88 KDR (1.00) KDRAURKATEKAURKBMET
SCHEMBL2748041 0.86 KDR (0.78) KDRAURKATEKAURKBMET
SCHEMBL2749427 0.86 KDR (1.00) KDRAURKATEKAURKBMET
SCHEMBL3760267 0.85 KDR (0.72) KDRAURKATEKAURKBMET
SCHEMBL2747562 0.85 KDR (1.00) KDRAURKATEKAURKBMET
SCHEMBL3758634 0.85 KDR (0.71) KDRAURKATEKAURKBMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176774-A1 Compounds and methods of use HGF, HGFAC, MET KDR 354/4885AURKA 4148/4885TEK 184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.